Európska únia - slovenčina - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinálne stromálne nádory - iné antineoplastické činidlá, protein kinase inhibítory - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

boston scientific neuromodulation corporation 25155 rye canyon loop valencia, ca spojené štáty americké -

Európska únia - slovenčina - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - ošípané - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

siemens healthcare gmbh henkestrasse 127 de-91052 erlangen nemecko -

Európska únia - slovenčina - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glykogénová choroba typu ii - iné alimentárny trakt a metabolizmus výrobky, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

alpha omega engineering ltd. hamerkava st. 6 1789 062 nof hagalil (nazareth illit) izrael -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

alpha omega engineering ltd. hamerkava st. 6 1789 062 nof hagalil (nazareth illit) izrael -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

alpha omega engineering ltd. hamerkava st. 6 1789 062 nof hagalil (nazareth illit) izrael -

Európska únia - slovenčina - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glykogénová choroba typu ii - iné alimentárny trakt a metabolizmus výrobky, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Európska únia - slovenčina - EMA (European Medicines Agency)

amicus therapeutics europe limited - miglustat - glykogénová choroba typu ii - ostatné produkty tráviaceho traktu a metabolizmu - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).